시장보고서
상품코드
1087858

세계의 의약품 수탁개발제조 시장 예측(-2029년) : 서비스별, 최종사용자별

Pharmaceutical Contract Development & Manufacturing Market by Service, End User [Large Pharma, Generic] - Global Forecast to 2029

발행일: | 리서치사: Meticulous Market Research Pvt. Ltd. | 페이지 정보: 영문 216 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 의약품 수탁개발제조 시장 규모는 2029년까지 2,263억 5,000만 달러에 달하고, 2022-2029년에 CAGR로 7.5%의 성장이 예측됩니다. 시장 성장은 주로 복잡한 제조 요건, 특허 만료, 의약품 연구개발에 대한 투자 증가, 의약품 업계의 최첨단 기술로의 지향, 코로나바이러스 유행 등에 기인하고 있습니다.

세계의 의약품 수탁개발제조(Pharmaceutical Contract Development & Manufacturing) 시장에 대해 조사 분석했으며, 시장 인사이트, 서비스·최종사용자별 분석, 경쟁 상황 등을 제공합니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 시장 인사이트

  • 서론
  • 성장 촉진요인
  • 과제
  • 시장 기회
  • 업계 동향

제5장 의약품 수탁개발제조 시장 : 서비스별

  • 서론
  • 의약품 제조 서비스
    • 원료의약품(API) 제조 서비스
    • 최종 제제(FDF) 제조 서비스
  • 의약품 개발 서비스
  • 생물제제 제조 서비스
    • 원료의약품(API) 제조 서비스
    • 최종 제제(FDF) 제조 서비스

제6장 의약품 수탁개발제조 시장 : 최종사용자별

  • 서론
  • 대형 제약 기업
  • 중소 제약 기업
  • 제네릭 제약 기업

제7장 의약품 수탁개발제조 시장 : 지역별

  • 서론
  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 독일
    • 영국
    • 프랑스
    • 이탈리아
    • 스페인
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 라틴아메리카
    • 브라질
    • 멕시코
    • 기타 라틴아메리카
  • 중동 및 아프리카

제8장 경쟁 상황

  • 서론
  • 주요 성장 전략
  • 경쟁 벤치마킹
  • 시장 점유율 분석(2021년) - 상위 19개사
    • Lonza Group Ltd.(스위스)
    • Catalent INC.(미국)
    • Thermo Fisher Scientific INC.(미국)
    • Samsung Biologics Co., Ltd.(한국)
    • Recipharm AB(스웨덴)

제9장 기업 개요(사업 개요, CDMO 시설, 재무 개요, 서비스 포트폴리오, 전략적 개발)

  • Cambrex Corporation
  • Samsung Biologics Co., Ltd.
  • Siegfried Holdings AG
  • FUJIFILM Diosynth Biotechnologies
  • Aenova Group
  • Wuxi Biologics, Inc.
  • Aurobindo Pharma, Ltd.
  • Vetter Pharma International GmbH
  • Thermo Fisher Scientific, Inc.
  • Catalent, Inc
  • Recipharm AB
  • Almac Group
  • Lonza Group Ltd.
  • Piramal Enterprises Limited
  • Fabbrica Italiana Sintetici S.p.A.
  • Fareva SA
  • C.H. Boehringer Sohn Ag & Co. KG.
  • Jubilant Pharmova Limited
  • Curia Global, Inc.

제10장 부록

KSM 22.06.21

Pharmaceutical Contract Development & Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Global Forecast to 2029

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029.

Following extensive secondary and primary research and an in-depth analysis of the market scenario, the report presents key industry drivers, restraints, challenges, and opportunities. The growth of the pharmaceutical contract development and manufacturing market is mainly attributed to complex manufacturing requirements, patent expiration, increasing investments in pharmaceutical R&D, the pharmaceutical industry's inclination towards cutting-edge technologies, and the outbreak of the coronavirus pandemic. Moreover, the growing demand for cell and gene therapies and personalized medicines and the growth of the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets offer significant opportunities for the players operating in the pharmaceutical contract development and manufacturing market.

Based on service, in 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share due to the growing need to reduce manufacturing costs, the use of advanced technologies and skills for manufacturing, the requirement for high-quality bulk manufacturing, and the growing demand for generic drugs. However, biologics manufacturing services is slated to be the fastest-growing segment during the analysis period due to the adoption of advanced technologies for biologics production, biopharma and pharma companies' inclination towards outsourcing their activities, increasing applications of monoclonal antibodies (mAbs), and the development of next-generation antibody therapies such as antibody-drug conjugates.

The API manufacturing services segment is expected to dominate the pharmaceutical contract manufacturing services market. The need to reduce the production cost of APIs, initiatives undertaken by pharmaceutical companies such as the development of new API manufacturing facilities, investments in API manufacturing services, agreements with other key players for expanding API manufacturing services, and the growing need to reduce the time required for drug development are expected to drive the growth of this segment.

Based on end user, the large pharmaceutical companies segment is estimated to command the largest share of the pharmaceutical contract development and manufacturing market in 2022. The rising incidence and prevalence of various diseases across the globe generating significant demand for effective medicines and breakthrough biopharmaceutical products and the growing need for state-of-the-art processes are the key factors driving the growth of the large pharmaceutical companies segment.

An in-depth analysis of the geographical scenario in the pharmaceutical contract development and manufacturing market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. North America is estimated to command the largest share of the pharmaceutical contract development and manufacturing market in 2022, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The key players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma-Fertigung GmbH & Co. KG (Germany), Piramal Enterprises Limited (India), Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group GmbH (Germany), WuXi Biologics (Cayman) Inc. (China), and Aurobindo Pharma Ltd. (India), among others.

Scope of the Report:

Pharmaceutical Contract Development and Manufacturing Market, by Service

  • Pharmaceutical Manufacturing Services
  • Pharmaceutical API Manufacturing Services
  • Pharmaceutical FDF Manufacturing Services
  • Parenteral/Injectable Manufacturing Services
  • Tablet Manufacturing Services
  • Capsule Manufacturing Services
  • Oral Liquid Manufacturing Services
  • Other Formulations Manufacturing Services
  • Drug Development Services
  • Biologics Manufacturing Services
  • Biologics API Manufacturing Services
  • Biologics FDF Manufacturing Services
  • Packaging Services

Pharmaceutical Contract Development and Manufacturing Market, by End User

  • Large Pharmaceutical Companies
  • Small and Mid-size Pharmaceutical Companies
  • Generic Pharmaceutical Companies

Pharmaceutical Contract Development and Manufacturing Market, by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Switzerland
    • Rest of Europe (RoE)
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • Rest of APAC (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions For The Study
  • 2.5. Limitations For The Study

3. Executive Summary

4. Market insights

  • 4.1. Introduction
  • 4.2. Drivers
    • 4.2.1. Complex Manufacturing Requirements of the Pharmaceutical industry and Manufacturers' Growing inclination

Toward the Use of Cutting-Edge Technologies

    • 4.2.2. Rising Demand for Generic Medicines and Biologics
    • 4.2.3. Patent Expiration
    • 4.2.4. Increasing Investments in Pharmaceutical R&D
    • 4.2.5. Outbreak of the COVID-19 Pandemic
  • 4.3. Challenges
    • 4.3.1. Shortage of Skilled Professionals
    • 4.3.2. Introduction of Serialization
  • 4.4. Opportunities
    • 4.4.1. Growing Demand for Cell Therapies, Gene Therapies, and Personalized Medicines
    • 4.4.2. Growth in High Potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) Markets
  • 4.5. Industry Trends
    • 4.5.1. Virtual Business Models
    • 4.5.2. Growing Consolidation Among CDMO Market Players

5. Pharmaceutical Contract Development and Manufacturing Services Market, by Type

  • 5.1. Introduction
  • 5.2. Pharmaceutical Manufacturing Services
    • 5.2.1. Active Pharmaceutical ingredient (API) Manufacturing Services
    • 5.2.2. Finished Dosage Forms (FDF) Manufacturing Services
      • 5.2.2.1. Parenteral/Injectable Manufacturing Services
      • 5.2.2.2. Tablet Manufacturing Services
      • 5.2.2.3. Capsule Manufacturing Services
      • 5.2.2.4. Oral Liquid Manufacturing Services
      • 5.2.2.5. Other Formulations
  • 5.3. Drug Development Services
  • 5.4. Biologics Manufacturing Services
    • 5.4.1. Active Pharmaceutical Manufacturing Services (API) Manufacturing Services
    • 5.4.2. Finished Dosage Form Manufacturing (FDF) Services

6. Pharmaceutical Contract Development and Manufacturing Market, by End User

  • 6.1. Introduction
  • 6.2. Large Pharmaceutical Companies
  • 6.3. Small & Mid-Size Pharmaceutical Companies
  • 6.4. Generic Pharmaceutical Companies

7. Pharmaceutical Contract Development and Manufacturing Market, By Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. U.S.
    • 7.2.2. Canada
  • 7.3. Europe
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe (RoE)
  • 7.4. Asia-Pacific
    • 7.4.1. China
    • 7.4.2. India
    • 7.4.3. Japan
    • 7.4.4. Rest of Asia-Pacific (ROAPAC)
  • 7.5. Latin America
    • 7.5.1. Brazil
    • 7.5.2. Mexico
    • 7.5.3. Rest of Latin America
  • 7.6. Middle East & Africa

8. Competitive Landscape

  • 8.1. Introduction
  • 8.2. Key Growth Strategies
  • 8.3. Competitive Benchmarking
  • 8.4. Market Share Analysis (2021) - TOP 19 Players
    • 8.4.1. Lonza Group Ltd. (Switzerland)
    • 8.4.2. Catalent INC. (U.S.)
    • 8.4.3. Thermo Fisher Scientific INC. (U.S.)
    • 8.4.4. Samsung Biologics Co., Ltd. (South Korea)
    • 8.4.5. Recipharm AB (Sweden)

9. Company Profiles (Business Overview, CDMO Facilities, Financial Overview, Service Portfolio, Strategic Developments)

  • 9.1. Cambrex Corporation
  • 9.2. Samsung Biologics Co., Ltd.
  • 9.3. Siegfried Holdings AG
  • 9.4. FUJIFILM Diosynth Biotechnologies
  • 9.5. Aenova Group
  • 9.6. Wuxi Biologics, Inc.
  • 9.7. Aurobindo Pharma, Ltd.
  • 9.8. Vetter Pharma international GmbH
  • 9.9. Thermo Fisher Scientific, Inc.
  • 9.10. Catalent, Inc
  • 9.11. Recipharm AB
  • 9.12. Almac Group
  • 9.13. Lonza Group Ltd.
  • 9.14. Piramal Enterprises Limited
  • 9.15. Fabbrica Italiana Sintetici S.p.A.
  • 9.16. Fareva SA
  • 9.17. C.H. Boehringer Sohn Ag & Co. KG.
  • 9.18. Jubilant Pharmova Limited
  • 9.19. Curia Global, Inc.

10. Appendix

  • 10.1. Questionnaire
  • 10.2. Available Customization
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제